Table 2. Clinical details of recurrent patients in the treatment and control groups.
| Covariates | Treatment group (n=52) | Control group (n=57) | P |
|---|---|---|---|
| HBV-DNA (IU/mL) | 0 (0-4.08×106) | 4.36×103 (0-1.46×107) | 0.013 |
| TBIL (μmol/L) | 12.35 (4.00-113.10) | 23.40 (3.40-298.70) | 0.04 |
| DBIL (μmol/L) | 4.00 (0.40-77.00) | 12.20 (2.80-129.80) | 0.043 |
| TP (g/L) | 70.53±6.51 | 68.43±6.43 | 0.093 |
| ALB (g/L) | 40.29±4.74 | 38.81±5.65 | 0.143 |
| ALT (U/L) | 36.50 (9.00-105.00) | 42.00 (13-218.00) | 0.021 |
| AST (U/L) | 35.50 (12.00-121.00) | 43.00 (15-344.00) | 0.04 |
| PT (s) | 13.27±1.38 | 13.93±1.82 | 0.032 |
| Recurrence in liver/Recurrence out of liver (%) | 48 (92.3)/4 (7.7) | 47 (82.5)/10 (17.5) | 0.125 |
| Tumor number, single nodule/multiple nodules (%) | 24 (46.2)/28 (53.8) | 20 (35.1)/37 (64.9) | 0.24 |
| Size of the largest tumor (cm) | 2.0 (0.4-7.0) | 3.2 (1.0-10.3) | 0.004 |
| Vascular invasion, yes/no (%) | 3 (5.8)/49 (94.2) | 7 (12.3)/50 (87.7) | 0.399 |
| Retreatment for recurrent HCC, radical treatments/palliative treatments (%) | 28 (53.8)/24 (46.2) | 19 (33.3)/38 (66.7) | 0.031 |